ADC Therapeutics SA (ADCT) Reports Q2 Loss of $0.51/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. GOOGL
3. MSFT
4. ENPH
5. GOOG
6. HOOD
7. SPY
8. BA
9. NXPI
10. STX

Go back to ADC Therapeutics SA (ADCT) Reports Q2 Loss of $0.51/sh

ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business Highlights

August 18, 2020 7:15 AM EDT

- On track to file BLA for Lonca for relapsed or refractory DLBCL later this year with commercial launch preparations ongoing

- Completed upsized $268 million initial public offering and received first tranche of $115 million Convertible Credit Facility from Deerfield

- Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with... More